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1. Introduction
Hepatitis B is caused by a 
virus that affects the liver, and 
when the infection progresses 
over time, it is called “chronic”. 
This can lead to liver damage 
as well as cause hepatic failure 
and hepatic cancer. The high 
prevalence of hepatitis B during 
pregnancy makes it an urgent 
problem, and the treatment of 
chronic viral hepatitis B during 
pregnancy is a difficult task. 
Scientists have found that de-
spite immunoprophylaxis, a sig-
nificant proportion of children 
born of mothers with high vire-
mia are infected with hepatitis 
B virus [1]. 
In the chronic viral hepatitis 
B (CVH B), the abortion in mild 
disease was noted in 7.7 %, in 
moderate – in 34.1 %, in severe – 
in 55.5 % of pregnant women. 
Pregnancy infertility is 15–20 %. 
In chronic viral hepatitis, the 
frequency of prematurity (mis-
carriage and premature birth) is 
significantly lower: 2 % and 10 %, 
respectively. Thus, chronic vi-
ral hepatitis B generally compli-
cates the course of pregnancy, 
childbirth and the postpartum 
period: the frequency of pre-
eclampsia increases (21.4 %), 
chronic fetoplacental insuffi-
ciency is more common (27.1 %), 
premature birth is more com-
mon (8.6 %), untimely discharge 
of amniotic f luid (16.8 %) and 
bleeding in the early postpar-
tum period (5.7 %). The accu-
mulated data make it possible to 
suggest that antiviral therapy in 
the III trimester of pregnancy is 
an effective measure [2]. 
Since liver damage in vi-
ral hepatitis B is predominantly 
immune-mediated, the activity of the hepatic process is often 
reduced in the second half of pregnancy due to hypercorti-
cism. Risk factors for exacerbation or complications of liver 
disease in connection with pregnancy are the presence of 
signs of activity of the liver and cholestasis, the presence of 
cirrhosis stage of the liver with signs of portal hypertension.
2. Methods
Theoretical analysis of scientific literature; analysis and 
generalization. Statistics and comparisons. Classification of 
theoretical material and development of recommendations. 
The solution of the tasks set in the work was carried out using 
a systematic approach in the selection of material, methods 
of inductive and logical analysis, observation and statistical 
methods of analysis of data. Characterizing viral hepatitis B 
during pregnancy, it should be 
noted that the main route of 
perinatal infection with CVH B 
is intranatal, although the trans-
placental transmission of CVH 
B in the III trimester of pregnan-
cy is also possible. The clinical 
picture of chronic viral hepatitis 
B during pregnancy is character-
ized as oligosymptomatic. How-
ever, the evidence-based sym- 
ptoms of hepatitis B in pregnant 
women may be asthenoneurotic 
disorders (unmotivated fatiga-
bility, unmotivated weakness, 
irritability and poor sleep, pain 
in the right hypochondrium); 
dyspeptic disorders (vomiting, 
nausea, loss of appetite, stool 
disorders, increased f latulence); 
cholestatic disorders (the emer-
gence of icterus as a result of im-
paired bile secretion, the pres-
ence of itching). 
3. Results
The results of a previous 
study, which included 17,951 ob- 
servations, showed that there is a 
linear correlation between failed 
immunoprophylaxis and the lev-
el of viremia in the mother [3]. 
This explained the increase in 
cases of ineffective preventive 
measures with increasing fre-
quency of high viremia in the mo- 
ther – more than 106 copies/ml. 
Experts of the First International 
Symposium on Hepatitis B Infec-
tion in Special Population (2009) 
recommended the use of anti-
viral medication to prevent the 
transmission of hepatitis B virus 
from mother [4]. 
Currently, the basis of mod-
ern treatment of viral hepatitis 
B is antiviral therapy (AT). At 
the same time, Peg-IFN is abso-
lutely contraindicated for pregnant women, lamivudine and 
entecavir are classified by the FDA as category C, and teno-
fovir and telbivudine are classified as category B (classifica-
tion is based on teratogenicity data obtained in preclinical 
studies). During pregnancy, it is recommended to use mainly 
category B medications [5] (Table 1).
Regarding the achievement of the stable clinical-labo-
ratory and virological remission of chronic hepatitis B, the 
effectiveness of interferon-alpha and nucleoside analogue 
lamivudine, tenofovir and telbivudine has been proven. Kip-
feron and suppositories for vaginal or rectal administration 
are used as immunocorrective treatment. Immunomodulatory 
and antiviral medication can provide a therapeutic effect up 
to eradication of the virus, but their use in pregnant women is 
contraindicated [6].
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The meta-analysis in 2017, which included 15 studies, 
showed that treatment of infected women with lamivudine 
from 28 weeks of pregnancy significantly reduced the likeli-
hood of vertical transmission of the infection (RR 0.33–0.43), 
and the effectiveness correlated with a reduction in viremia to 
200,000 IU/ml [7]. The safety of lamivudine administration 
during pregnancy remains open – due to insufficient human 
studies, the FDA classifies it for pregnant women as a category 
C drug (data based on animal studies that have shown adverse 
effects on the fetus). Another disadvantage of lamivudine is the 
high frequency of drug resistance, which develops during the 
year in 15 % of patients treated [8].
It has also been established that mothers with baseline liver 
cirrhosis due to chronic hepatitis B have a high risk of perinatal 
complications. The results of a population-based study (obser-
vation period – from 1993 to 2005) showed that the risk of de-
veloping liver failure during pregnancy in women with cirrhosis 
is on average 15 %. Maternal mortality and perinatal fetal death 
in such cases are 1.8 and 5.2 %, respectively. These data serve as 
a good basis for earlier appointment of antiviral therapy during 
pregnancy or continuation of treatment already started before 
pregnancy. Although this tactic is associated with more frequent 
cases of prematurity and stunted children, it helps reduce the risk 
of gestational hypertension, placental abruption, bleeding during 
childbirth – complications that contribute significantly to mater-
nal mortality. The drug of choice in this case is tenofovir.
Tenofovir, in comparison with lamivudine, has better efficacy 
and lower frequency of drug resistance, so in recent years this 
drug is recommended as the first line of chemoprophylaxis of 
perinatal infection in pregnant women [9]. Tenofovir for pregnant 
women according to the FDA classification belongs to catego- 
ry B, the absence of its teratogenic effect has been confirmed 
by several PCI. EASL (2015) recommends initiating tenofovir 
therapy in women with DNA CVH B levels above 200,000 IU/ml 
or HBsAg levels greater than 4 log10 IU/ml from 24–28 weeks 
of pregnancy and continuing for 12 weeks after the act of de-
livery. Some researchers, addressing the question of initiating 
chemotherapy with tenofovir during pregnancy, recommend to 
focus on the level of AST or ALT, which exceeds the norm by 
1.5–2 times as an additional criterion for assessing viremia.
Telbivudine for pregnant women according to the FDA 
classification belongs to category B and has shown efficacy in 
the prevention of perinatal infection when used in the second 
or third trimester in HBsAg-positive mothers with viremia 
levels >200,000 IU/ml. In a study telbivudine at a dose of 
600 mg/day was administered from 20 to 32 weeks of pregnancy 
to 135 women with high viremia, whose children were given a 
hepatitis B vaccine and a specific immunoglobulin after deliv-
ery. At 28 weeks postpartum, perinatal infection in children was 
found in 0 % of the women receiving telbivudine and in 8 % of 
the group of women not receiving chemotherapy.
High resistance to immunoprophylaxis occurs only in 
HBsAg-positive women with high levels of DNA СVH B 
(>200,000 IU/ml) and/or HBsAg levels above 4 log10 IU/ml, 
so in the third trimester of pregnancy such women are rec-
ommended chemoprophylaxis with lamivudine, tenofir and 
telbivudine, among which tenofovir is the most acceptable. The 
duration of chemoprophylaxis of nucleoside analogues (NA) is 
not precisely defined and can be stopped both before childbirth 
and 3 months after childbirth.
Due to the short duration of therapy with lamivudine and 
telbivudine (8–12 weeks) in the III trimester of pregnancy, 
resistance to these drugs in the treatment of pregnant women 
who have not previously received antiviral therapy, develops 
very rarely [10]. Tenofovir is recommended for the treatment 
of patients with appropriate indications due to its favourable 
safety profile and potentially high activity in suppressing 
viral replication. European Association for the Study of the 
Liver (EASL) [11] and the American Association for the Study 
of Liver Diseases (AASLD), classified the tenofovir therapy as 
first-line one [12]. In addition, the replacing of antiviral drug 
with tenofovir is recognized as a more effective tactic for the 
treatment of pregnant women with already developed resistance 
to nucleoside analogues.
Thus, the tactics in antiviral therapy of pregnant women 
with chronic HBV infection is the following:
– in the absence of indications for antiviral therapy and 
viral load of HBV DNA less than 1,000,000 IU/ml, the patient is 
subject to dynamic monitoring;
– in case of liver disease less than F3 and viral load of HBV 
DNA less than 1,000,000 IU/ml, therapy may be delayed until 
delivery [13];
– in the absence of active liver disease, stage less F3 and high 
viral load of HBV DNA (1,000,000 IU/ml and more), especially 
with HBeAg-positive status, there is a high risk of vertical in-
fection (10 %), despite the active and passive immunization of 
the child. Such drugs (tenofovir or telbivudine or lamivudine) 
Table 1
Toxicity categories of antiviral therapy taken during pregnancy (FDA Classification)
Category Effects on the fetus Antiviral treatment
А The results of controlled studies did not reveal a risk to the fetus in the first trimester of pregnancy; there is no evidence of risk in subsequent trimesters of pregnancy –
В
The results of animal studies did not reveal a risk to the fetus; the results of controlled studies on 
pregnant women or animals did not reveal side effects of the medicament on the fetus; controlled 




Animal studies have shown negative effects on the fetus; controlled human studies have not been 
conducted; the potential benefit of the medicament in pregnant women outweighs the potential 





There are data on the negative effects of the treatment on the fetus, obtained in controlled and 
post-marketing studies, but the potential benefits of the medicament for pregnant women may 
outweigh the potential risk to the fetus
–
X
The results of controlled and post-marketing studies in animals and humans revealed abnormali-
ties in fetal development; the risk associated with the use of the medicament in pregnant women 
far outweighs the potential benefits
interferon
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are prescribed to women to prevent perinatal transmission 
throughout the 3rd trimester. Control determination of HBV 
DNA is performed after 8 weeks, and the drug is recommended 
to continue for 12 weeks after delivery. In the future, the need 
for AT is determined by general indicators;
– in the case of active liver disease with severe fibrosis or 
cirrhosis, standard AT is recommended using category B drugs, 
the most preferred of which is tenofovir.
Summing up, it can be stated that antiviral therapy in preg-
nant women remains a difficult task and requires individual and 
detailed assessment of the risks of medical exposure to the fetus 
in comparison with the benefits of treatment [13]. The positive 
effects of antiviral therapy include a significant reduction in 
the transmission of hepatitis B virus from mother to fetus in 
patients with high viremia, as well as the provision of therapeu-
tic control of chronic hepatitis B as prevention of progression 
of liver fibrosis/cirrhosis. Finally, the use of antiviral therapy 
in combination with immunoprophylaxis of new-borns is the 
optimal strategy for implementation as a universal program, as 
the success of such an intervention can make a significant con-
tribution to achieving the ultimate goal of global elimination of 
hepatitis B virus.
5. Conclusions
In order to detect pregnant women infected with hepatitis 
B virus in a timely manner, it is necessary to examine women 
for hepatitis B virus antigen (HBsAg). It is necessary to conduct 
timely medical examination of pregnant women for early detec-
tion of pregnancy complications and threatening conditions in 
the fetus.
In addition, to minimize the effect of nucleotide and nucleo-
side analogues on the fetus, antiviral therapy during pregnancy 
should be prescribed to mothers at high risk of disease progres-
sion and decompensation of hepatitis B virus infection. The 
safety data suggest that telbivudine and tenofovir may be used 
during pregnancy. However, antiviral therapy requires careful 
risk and benefit assessment.
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